Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7 Neoplasms 4 Advanced Cancer 4 Lymphoma, Non-Hodgkin 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Lymphoma, Large B-Cell, Diffuse 2 Liver Neoplasms 2 Hodgkin Disease 2 Various Advanced Cancer 1 Uveal Melanoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms by Site 1 Microsatellite Unstable Colorectal Cancer 1 Melanoma, Cutaneous Malignant 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Burkitt Lymphoma 1 Advanced Solid Tumors 1

Interventions

Nivolumab 5 Ipilimumab 3 relatlimab 1 daratumumab 1 Fluorouracil 1 Cisplatin 1 BMS-986115 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Various Advanced Cancer × relatlimab × Clear all

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡